These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 33280239)

  • 1. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis.
    Li L; Wei T; Liu S; Wang C; Zhao M; Feng Y; Ma L; Lu Y; Fu P; Liu J
    J Cell Mol Med; 2021 Jan; 25(2):960-974. PubMed ID: 33280239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.
    Li L; Chen L; Zang J; Tang X; Liu Y; Zhang J; Bai L; Yin Q; Lu Y; Cheng J; Fu P; Liu F
    Metabolism; 2015 May; 64(5):597-610. PubMed ID: 25682062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility.
    Tan SM; Ziemann M; Thallas-Bonke V; Snelson M; Kumar V; Laskowski A; Nguyen TV; Huynh K; Clarke MV; Libianto R; Baker ST; Skene A; Power DA; MacIsaac RJ; Henstridge DC; Wetsel RA; El-Osta A; Meikle PJ; Wilson SG; Forbes JM; Cooper ME; Ekinci EI; Woodruff TM; Coughlan MT
    Diabetes; 2020 Jan; 69(1):83-98. PubMed ID: 31624141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells.
    Zitman-Gal T; Einbinder Y; Ohana M; Katzav A; Kartawy A; Benchetrit S
    J Diabetes; 2019 Aug; 11(8):656-664. PubMed ID: 30575282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy.
    Yiu WH; Li RX; Wong DWL; Wu HJ; Chan KW; Chan LYY; Leung JCK; Lai KN; Sacks SH; Zhou W; Tang SCW
    Nephrol Dial Transplant; 2018 Aug; 33(8):1323-1332. PubMed ID: 29294056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Regulatory Effect of Pyruvate Kinase M2 is Involved in Renal Inflammation in Type 2 Diabetic Nephropathy.
    Li L; Tang L; Yang X; Chen R; Zhang Z; Leng Y; Chen AF
    Exp Clin Endocrinol Diabetes; 2020 Sep; 128(9):599-606. PubMed ID: 31958846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allograft inflammatory factor-1 enhances inflammation and oxidative stress via the NF-κB pathway in diabetic kidney disease.
    Fu Y; Wang X; Zhang L; Ren Y; Hao L
    Biochem Biophys Res Commun; 2022 Jul; 614():63-69. PubMed ID: 35569377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.
    Lei YC; Lu CL; Chen L; Ge K; Yang LL; Li W; Wu YH
    World J Gastroenterol; 2016 Dec; 22(46):10148-10157. PubMed ID: 28028363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial CXCR2 deficiency attenuates renal inflammation and glycocalyx shedding through NF-κB signaling in diabetic kidney disease.
    Cui S; Chen X; Li J; Wang W; Meng D; Zhu S; Shen S
    Cell Commun Signal; 2024 Mar; 22(1):191. PubMed ID: 38528533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in
    Yan H; Zhang Y; Lin X; Huang J; Zhang F; Chen C; Ren H; Zheng S; Yang J; Hui S
    Int J Food Sci Nutr; 2024 May; 75(3):264-276. PubMed ID: 38238900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorogenic acid alleviates renal fibrosis by reducing lipid accumulation in diabetic kidney disease through suppressing the Notch1 and Stat3 signaling pathway.
    Yang XY; Jiang D; Wang YZ; Duan MY; Huang YW; Wang XJ; Xiang ZM; Sheng J; Zhu QQ
    Ren Fail; 2024 Dec; 46(2):2371988. PubMed ID: 38952291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
    Zaky A; Glastras SJ; Wong MYW; Pollock CA; Saad S
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-223-3p mediates the diabetic kidney disease progression by targeting IL6ST/STAT3 pathway.
    Tang P; Xu Y; Zhang J; Nan J; Zhong R; Luo J; Xu D; Shi S; Zhang L
    Biochem Biophys Res Commun; 2023 Mar; 648():50-58. PubMed ID: 36731227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.
    Tao P; Ji J; Wang Q; Cui M; Cao M; Xu Y
    Front Immunol; 2022; 13():1080456. PubMed ID: 36601125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement C5 mediates experimental tubulointerstitial fibrosis.
    Boor P; Konieczny A; Villa L; Schult AL; Bücher E; Rong S; Kunter U; van Roeyen CR; Polakowski T; Hawlisch H; Hillebrandt S; Lammert F; Eitner F; Floege J; Ostendorf T
    J Am Soc Nephrol; 2007 May; 18(5):1508-15. PubMed ID: 17389734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
    Zhong C; Dai Z; Chai L; Wu L; Li J; Guo W; Zhang J; Zhang Q; Xue C; Lin H; Luo Q; Cai K
    J Clin Lab Anal; 2021 Dec; 35(12):e24062. PubMed ID: 34689373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease.
    Trambas IA; Coughlan MT; Tan SM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice.
    Liu W; Chen X; Wang Y; Chen Y; Chen S; Gong W; Chen T; Sun L; Zheng C; Yin B; Li S; Luo C; Huang Q; Xiao J; Xu Z; Peng F; Long H
    Pharmacol Res; 2019 Dec; 150():104506. PubMed ID: 31669149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice.
    Wu J; Chen Y; Yang H; Gu L; Ni Z; Mou S; Shen J; Che X
    Front Endocrinol (Lausanne); 2023; 14():1026040. PubMed ID: 36777358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.